Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | CNR1 | P21554 | 13/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenabasum SCHEMBL29872156 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL7056887 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL26441 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL17414503 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL13035015 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL23202520 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL29362927 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL6406468 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL29611496 | 0.99 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL14501182 | 0.99 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063697-A1 | Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2021113669-A1 | CANNABINOIDS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20040063697-A1 | Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063697-A1 | Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event | PTGIS, PTGIR, PTGS2 | CNR2 328/4885CNR1 1000/4885GLRA1 2551/4885 |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | CNR2 113/4885CNR1 200/4885GLRA1 2487/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | CNR2 113/4885CNR1 200/4885GLRA1 2487/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | CNR2 3101/4885CNR1 2718/4885GLRA1 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.